证券代码：002007 证券简称：华兰生物 公告编号：2026-003 注册分类：治疗用生物制品 1 类 申请类型：新药 华兰生物工程股份有限公司 关于收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 2026 年 2 月 2 日，华兰生物工程股份有限公司（以下简称"公司"）收到 国家药品监督管理局下发的《药物临床试验批准通知书》（通知书编号：2026L P00310）。现将相关情况公告如下： 一、药物基本情况 药物名称：重组 Exendin-4-Fc 融合蛋白注射液（以下简称"HL08"） 三、对公司的影响及风险提示 本次 HL08 新增适应症临床试验获批，标志着药物可正式开展对应临床研究， 进一步验证安全性与有效性，为后续注册上市奠定基础，同时丰富公司生物药产 品管线，优化产品结构。 药品研发具有周期长、环节多、风险高的特点，本品后续尚需完成全部临床 试验、生产申报、国家药监局审批等环节，各环节结果均存在不确定性；同时面 临临床数据与进度不及预期、市场竞争激烈、行业政策及技术迭代变化等风险， 可能影响最终研发成果与市场表现。 ...

Core Viewpoint - The company Hualan Biological (002007.SZ) has received approval from the National Medical Products Administration for clinical trials of a new drug, HL08, which is aimed at improving weight control in obese patients in addition to its original indication for type 2 diabetes management [1] Group 1 - The drug HL08 is a recombinant Exendin-4-Fc fusion protein injection [1] - The original indication for HL08 was to improve blood glucose control in patients with type 2 diabetes [1] - The newly approved indication expands its use to include weight control in obese patients [1]

Core Viewpoint - The company Hualan Biological (002007.SZ) has received approval from the National Medical Products Administration for a new drug clinical trial, expanding the indications for its drug HL08 to include weight control in obese patients in addition to its original indication for improving blood glucose control in type 2 diabetes patients [1] Group 1 - The drug HL08 is a recombinant Exendin-4-Fc fusion protein injection [1] - The original indication for HL08 was to improve blood glucose control in patients with type 2 diabetes [1] - The newly approved indication aims to assist in weight control for obese patients [1]

Core Viewpoint - The company, Hualan Biological (002007.SZ), has received approval from the National Medical Products Administration for its drug, HL08, a new generation GLP-1 receptor agonist developed in-house [1] Group 1: Drug Development - HL08 is a recombinant Exendin-4-Fc fusion protein injection [1] - The active ingredient of HL08 is a recombinant Exendin-4-Fc fusion protein, which combines Exendin-4 with the Fc fragment of IgG2 antibody [1] - The drug significantly extends the biological half-life while retaining the natural physiological functions of Exendin-4, enhancing medication convenience and therapeutic efficacy [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for a new drug, HL08, which is a recombinant Exendin-4-Fc fusion protein injection aimed at treating type 2 diabetes and obesity [1] Group 1: Drug Approval Details - The approval notification was issued on February 2, 2026, under the notification number 2026LP00310 [1] - HL08 is classified as a Class 1 therapeutic biological product and is categorized as a new drug [1] Group 2: Drug Characteristics - HL08 is a next-generation GLP-1 receptor agonist developed by the company [1] - The active ingredient is a recombinant Exendin-4-Fc fusion protein, which combines Exendin-4 with the Fc fragment of IgG2 antibody [1] - This fusion significantly extends the biological half-life of the drug, enhancing convenience and sustained efficacy in treatment [1] Group 3: Indications - The original approved indication for HL08 was to improve blood glucose control in patients with type 2 diabetes [1] - An additional indication has been approved for improving weight control in obese patients [1]

Core Insights - The report outlines the achievements and future goals of the Henan provincial government, emphasizing economic growth, social development, and environmental sustainability during the "14th Five-Year Plan" period and the upcoming "15th Five-Year Plan" period. Economic Performance - The province's GDP reached 6.66 trillion yuan, with a fiscal revenue of 701.9 billion yuan and industrial revenue of 5 trillion yuan, indicating steady economic growth despite challenges [4] - In 2025, the GDP growth was 5.6%, with industrial added value increasing by 8.4% and social retail sales growing by 5.6% [9] Industrial Development - Strategic emerging industries accounted for over 25% of the industrial added value, with significant contributions from advanced equipment, electronic information, and new energy vehicles [5] - The province has cultivated leading enterprises in various sectors, including BYD and CATL, and established three global "lighthouse factories" [5] Agricultural Advancements - Grain production has remained stable at over 1.3 trillion jin for nine consecutive years, with significant improvements in agricultural mechanization and infrastructure [6] - The province has developed 11 new national modern agricultural industrial parks and 119 leading agricultural enterprises [6] Reform and Opening Up - Comprehensive reforms in state-owned enterprises have been implemented, with 19 enterprises undergoing strategic restructuring [7] - The province has seen a surge in private sector activity, with 3.7 million new business entities established [7] Environmental Protection - The province has exceeded national air pollution control targets, with water quality in the Yellow River reaching Class II for six consecutive years [7] - Significant efforts have been made in afforestation and soil erosion control, with over 6.59 million mu of trees planted [7] Social Welfare - Urban employment increased by 603.7 million, with a focus on improving living standards and public services [8] - The province has made strides in education, with an increase in higher education enrollment rates and the establishment of new universities [8] Future Goals - The "15th Five-Year Plan" aims for an average annual economic growth of around 5%, with a focus on expanding effective demand and integrating into the national market [15] - Key targets include increasing the urbanization rate to 65% and enhancing agricultural production capacity to 1.4 trillion jin [16] Key Initiatives - The government plans to implement over 1,000 key projects with an annual investment of 1 trillion yuan, focusing on infrastructure and energy systems [24] - The province aims to strengthen its modern industrial system, particularly in advanced manufacturing and service sectors [25][26] Cultural and Environmental Initiatives - The report emphasizes the importance of cultural heritage protection and the integration of cultural and tourism industries [33] - Environmental initiatives include a comprehensive plan for carbon peak and pollution reduction, aiming for a sustainable ecological environment [35][36]

Core Viewpoint - The company, Hualan Vaccine, emphasizes its strong collaboration with its controlling shareholder, Hualan Biological, in various aspects such as biopharmaceutical research and development, production quality system construction, supply chain management, and compliance experience [1] Group 1 - The company and Hualan Biological are committed to building and managing the "Hualan" brand, which has been recognized as a well-known trademark in China, indicating good market recognition and brand reputation [1] - Some vaccine products from the company have complementary clinical applications with related immunological products from Hualan Biological, such as rabies vaccine and tetanus vaccine, which can be used in conjunction with corresponding human immunoglobulin to achieve synergistic effects of active and passive immunity [1]

Core Viewpoint - The company, Hualan Vaccine, emphasizes its collaborative development with its controlling shareholder, Hualan Biological, focusing on shared resources and complementary product offerings in the vaccine sector [1] Group 1: Collaboration and Synergy - The company and Hualan Biological have established a solid foundation for collaboration in areas such as bioproduct research and development management, production quality system construction, supply chain management, and compliance experience [1] - Both entities are committed to the construction and management of the "Hualan" brand, which has been recognized as a famous trademark in China, indicating strong market recognition and brand reputation [1] Group 2: Product Complementarity - Certain vaccine products from the company have complementary applications with Hualan Biological's related immunological products, such as rabies vaccine and tetanus vaccine, which can be used in conjunction with corresponding human immunoglobulin to enhance both active and passive immunity [1]

创新药概念局部活跃，消息面上，新修订的《中华人民共和国药品管理法实施条例》将于5月15日起施 行。国家药监局表示，这是条例实施二十多年来，首次全面修订。支持以临床价值为导向研究和创制新 药，提升仿制药质量和疗效。 中信证券研报称，2026年1月，阿里健康、京东健康两家头部医药电商平台相继正式发布面向医生的AI 医疗应用产品。看好头部医药电商平台凭借上游药企、下游C端用户资源，以及其母公司具备的AI基模 能力与产品能力，在ToD AI医疗应用领域脱颖而出，并率先跑通商业模式，实现AI医疗对主业的增收 赋能。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年1月28日 11:09，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，兴齐眼药领涨 1.42%，新和成上涨1.27%，片仔癀上涨0.27%；英科医疗领跌2.47%，华兰生物下跌2.22%，恩华药业下 跌2.22%。医疗创新ETF ...

Group 1: Currency and Economic Indicators - The US dollar index experienced a significant drop, reaching a low of 95.5542, the lowest since February 2022, following comments from Trump expressing indifference towards the dollar's decline [1] - The People's Bank of China reported that by the end of Q4 2025, the total balance of RMB loans was 271.91 trillion yuan, a year-on-year increase of 6.4%, with a total increase of 16.27 trillion yuan for the year [5] Group 2: Corporate Developments - The actual controller of Dongcai Technology, Yichang Technology, and Gaomeng New Materials, Xiong Haitao, is under investigation by the Sichuan Provincial Supervisory Committee [3] - Multiple semiconductor companies announced price increases, with prices for certain products rising by 15% to 50% for Zhongwei Semiconductor and up to 80% for Guokewi [3] - A number of A-share companies reported their 2025 earnings forecasts, with Shijia Photon expecting a revenue increase of approximately 98.13% and a net profit increase of about 425.95% [20] - Vanke A announced that its largest shareholder, Shenzhen Metro Group, will provide a loan of up to 2.36 billion yuan to repay bond principal and interest [25] - Di'er Laser is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy [29] Group 3: Regulatory and Policy Changes - The Ministry of Natural Resources, the Ministry of Civil Affairs, and the National Health Commission jointly issued 18 measures to support the development of elderly care services, including encouraging mixed-use land development [7] - The revised Drug Administration Law will take effect on May 15, emphasizing the importance of clinical value in drug research and introducing exclusive market periods for pediatric and rare disease drugs [12] - The Ministry of Human Resources and Social Security announced plans to implement employment support measures in response to the impact of artificial intelligence [9]